We take pleasure in presenting the third daily highlight from the ASH 2023...
The current standard of care for patients with NDMM involves four cycles of VRd...
The ZUMA-12 study represents a phase 2 clinical trial aimed at investigating...
Allogeneic CAR T-cell therapies represent a potentially readily accessible...
The therapeutic potential of inhibiting NETs in various pathological conditions...
Dr Sharman presents the 6-year follow-up outcomes of the ELEVATE-TN study, a...
Dr Rutger Callens, a haematologist at AZ Delta in Roeselare, graciously...
Approximately 30% of pediatric AML patients encounter relapse, emphasizing the...
An innovative decentralized and automated PoC manufacturing paradigm was...
Dr Frida Bugge Askeland, associated research doctor and PhD student at the Oslo...